

October 29, 2024

To
The Corporate Relations Department
BSE Limited,
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai - 400001
Company Code No. 526301

Dear Sir/Madam,

Subject: Outcome of the Board Meeting held on October 29, 2024.

We hereby inform you that, the Board of Directors in their meeting held today i.e. on **Tuesday, October 29, 2024** has inter-alia considered and approved:

1. The Un-audited Standalone and Consolidated Financial Results of the Company for the Second Quarter and Half Year ended September 30, 2024.

A signed copy of the above Financial Results along with Limited Review Report issued by the Statutory Auditors thereon under Regulation 33 of the Listing Regulations are enclosed to this letter.

The Meeting commenced at 12:30 P.M. (IST) and concluded at 1:45 P.M. (IST).

Kindly take the same on record.

Thanking You.

For **Medinova Diagnostic Services Limited**

HANSRA Digitally signed
by HANSRAJ
SINGH
J SINGH Date: 2024.10.29
13:47:54 +05'30'

Hansraj Singh
Company Secretary & Compliance Officer
M.No.F11438

M.ANANDAM & CO.,
CHARTERED ACCOUNTANTS

**Independent Auditor's Review Report on the Quarterly Consolidated Unaudited Financial Results of
the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015**

**Review Report to the Board of Directors
Medinova Diagnostic Services Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Medinova Diagnostic Services Limited ("the Holding Company") and its wholly owned subsidiary (the Holding Company and its subsidiary together referred to as "the Group") for the quarter ended 30th September, 2024 and year to date results for the period 1st April, 2024 to 30th September, 2024 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. The Statement includes the results of the wholly owned subsidiary, Medinova Millenium MRI Services LLP.

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited consolidated financial results, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M. Anandam & Co.,
Chartered Accountants
(Firm Regn.No.000125S)

Madhuri Digitally signed by
Chimalgi Madhuri Chimalgi
Date: 2024.10.29
13:29:59 +05'30'

Madhuri Chimalgi
Partner
Membership Number: 235955

UDIN: 24235955BKCJZP2553

Place: Secunderabad
Date: 29-10-2024

MEDINOVA DIAGNOSTIC SERVICES LIMITED

CIN: L85110TG1993PLC015481

Regd. Office : H.No. 7-1-58, Unit No. 1/Flat No.301, 3rd Floor, Amrutha Business Complex, Ameerpet, Hyderabad - 500 016.

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30th SEPTEMBER, 2024

(Rs. in Lakhs)

Sl. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2024 (Unaudited)	30.06.2024 (Unaudited)	30.09.2023 (Unaudited)	30.09.2024 (Unaudited)	30.09.2023 (Unaudited)	31.03.2024 (Audited)
1	Income:						
	(a) Revenue from Operations	256.08	249.05	286.80	505.13	528.50	1,016.52
	(b) Other Income	2.55	1.67	1.67	4.22	3.59	19.82
	Total Income	258.63	250.72	288.47	509.35	532.09	1,036.34
2	Expenses						
	(a) Cost of Materials Consumed	17.66	20.54	28.64	38.20	54.09	100.29
	(b) Employee Benefits Expense	45.94	47.15	47.24	93.09	99.82	190.40
	(c) Testing Fees	19.84	15.02	15.73	34.86	26.04	49.86
	(d) Finance Costs	12.60	12.47	14.49	25.07	28.83	57.40
	(e) Depreciation	3.61	3.26	3.27	6.87	6.21	12.73
	(f) Other Expenses	92.60	96.83	104.28	189.43	204.58	397.77
	Total Expenses	192.25	195.27	213.65	387.52	419.57	808.45
3	Profit before Tax	66.38	55.45	74.82	121.83	112.52	227.89
4	Tax Expense						
	(a) Current Tax	15.67	9.45	7.00	25.12	7.50	20.39
	(b) Earlier Year's Tax	-	-	0.01	-	0.01	0.01
	(c) Deferred Tax	0.95	3.76	1.40	4.71	5.30	7.60
	Total tax expense	16.62	13.21	8.41	29.83	12.81	28.00
5	Profit/Loss for the period (3-4)	49.76	42.24	66.41	92.00	99.71	199.89
6	Other Comprehensive Income						
	Items that will not be reclassified to Profit or Loss :						
	i) Remeasurement of defined benefit plans	-	-	-	-	-	1.63
	ii) Income tax relating to above	-	-	-	-	-	(0.41)
7	Total Comprehensive Income for the period (5+6)	49.76	42.24	66.41	92.00	99.71	201.11
	Net Profit attributable to:						
	(a) Owners of the Company	49.76	42.24	66.41	92.00	99.71	199.89
	(b) Non Controlling Interest	-	-	-	-	-	-
	Other Comprehensive Income attributable to:						
	(a) Owners of the Company	-	-	-	-	-	1.22
	(b) Non Controlling Interest	-	-	-	-	-	-
	Total Comprehensive Income attributable to:						
	(a) Owners of the Company	49.76	42.24	66.41	92.00	99.71	201.11
	(b) Non Controlling Interest	-	-	-	-	-	-
8	Paid-up Equity Share capital (Face Value Rs 10/- per share)	995.68	995.68	995.68	995.68	995.68	995.68
9	Earnings per Equity Share (not annualised)						
	a) Basic (Rs.)	0.50	0.42	0.67	0.92	1.00	2.00
	b) Diluted (Rs.)	0.50	0.42	0.67	0.92	1.00	2.00

Notes

1. The above Consolidated financial results of Medinova Diagnostic Services Limited ("the Company") have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2. The above consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 29th October, 2024. The statutory auditors have carried out limited review of the above results for the quarter and half year ended 30 September 2024. An unmodified report has been issued by them thereon.

3. The above results include the results of the wholly owned subsidiary, Medinova Millennium MRI Services LLP

4. The Group has one reportable segment (viz. Diagnostic Services) as per the requirements of Ind AS 108 "Operating Segments".

5. The Group has prepared consolidated financial results based on Ind AS 110 "Consolidated Financial Statements".

6. The Board of Directors of the Company in their meeting held on June 26th 2024, have considered and approved the proposed Scheme of Amalgamation of the Company ("Transferor Company") into and with the Parent Company, "Vijaya Diagnostic Centre Limited" (Transferee Company) with effect from April 01st, 2024 ("the Appointed Date") under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013, and other rules and regulations framed thereunder ("Scheme").

The aforesaid Scheme is subject to the approval of Stock Exchanges, SEBI, Shareholders and Creditors of the respective companies and National Company Law Tribunal, and such other approvals, permissions, and sanctions of regulatory and other authorities as may be necessary.

For MEDINOVA DIAGNOSTIC SERVICES LIMITED

SURA SURENDRANATH REDDY Digitally signed by SURA SURENDRANATH REDDY
Date: 2024.10.29 13:04:08 +05'30'

DR. S. SURENDRANATH REDDY
CHAIRMAN
DIN 00108599

Place: Hyderabad

Date : 29-10-2024

MEDINOVA DIAGNOSTIC SERVICES LIMITED

CIN: L85110TG1993PLC015481

Regd. Office : H.No. 7-1-58, Unit No. 1/Flat No.301, 3rd Floor, Amrutha Business Complex, Ameerpet, Hyderabad - 500 016.

Consolidated Balance Sheet as at September 30, 2024

(Rs. in Lakhs)

Sl No.	Particulars	As at 30.09.2024 (UnAudited)	As at 31.03.2024 (Audited)
	ASSETS		
I	Non-current assets		
	(a) Property, plant and equipment	186.84	159.92
	(b) Intangible assets	3.73	3.64
	(c) Financial assets		
	(i) Other financial assets	60.00	55.27
	(d) Deferred tax assets, (net)	42.65	47.36
	(e) Non-current tax assets, (net)	11.89	11.89
	Total non-current assets	305.11	278.08
II	Current assets		
	(a) Inventories	14.88	13.58
	(b) Financial assets		
	(i) Trade receivables	57.15	42.58
	(ii) Cash and cash equivalents	248.74	191.49
	(iii) Other financial assets	2.22	3.25
	(c) Current tax assets (net)	3.50	2.71
	(d) Other current assets	6.65	6.36
	Total current assets	333.14	259.97
	TOTAL ASSETS (I + II)	638.25	538.05
	EQUITY AND LIABILITIES		
I	Equity		
	(a) Equity share capital	995.68	995.68
	(b) Other equity	(1,216.15)	(1,308.14)
	Total equity	(220.47)	(312.46)
	Liabilities		
II	Non-current liabilities		
	(a) Financial liabilities		
	(i) Borrowings	500.00	500.00
	(b) Provisions	16.84	22.19
	Total non-current liabilities	516.84	522.19
	Current liabilities		
	(a) Financial liabilities		
	(i) Trade payables		
	(a) Total outstanding dues of micro and small enterprises	0.80	3.70
	(b) Total outstanding dues of creditors other than micro and small enterprises	245.53	233.45
	(ii) Other financial liabilities	31.64	34.26
	(b) Other current liabilities	12.47	6.67
	(c) Provisions	48.35	48.34
	(d) Current Tax liabilities	3.09	1.90
	Total current liabilities	341.88	328.32
	Total liabilities (II + III)	858.72	850.51
	TOTAL EQUITY AND LIABILITIES (I + II + III)	638.25	538.05

For MEDINOVA DIAGNOSTIC SERVICES LIMITED

SURA
SURENDRANATH
REDDY

Digitally signed by SURA
SURENDRANATH REDDY
Date: 2024.10.29 13:05:01
+05'30'

DR. S. SURENDRANATH REDDY

CHAIRMAN

DIN 00108599

Place: Hyderabad

Date : 29-10-2024

MEDINOVA DIAGNOSTIC SERVICES LIMITED

CIN: L85110TG1993PLC015481

Regd. Office : H.No. 7-1-58, Unit No. 1/Flat No.301, 3rd Floor, Amrutha Business Complex, Ameerpet, Hyderabad - 500 016.

Consolidated Statement of Cash Flows

(Rs. in Lakhs)

	Half Year ended September 30, 2024 (Unaudited)	Half Year ended September 30, 2023 (Unaudited)
A. Cash flow from operating activities		
Profit before tax	121.83	112.52
<i>Adjustments for:</i>		
Depreciation expense	6.87	6.21
Net (gain)/Loss on sale of property, plant and equipment	3.20	-
Interest income	(3.93)	(2.08)
Provision for credit impaired receivables	-	6.00
Liabilities no longer required written back	-	0.19
Finance costs	25.07	28.83
Operating profit before changes in assets and liabilities	153.04	151.67
Changes in working capital:		
(Increase)/ decrease in trade receivables	(14.55)	8.46
(Increase)/ decrease in inventories	(1.30)	(1.18)
(Increase)/ decrease in other financial assets	(4.73)	(0.21)
Decrease/(Increase) in other tax assets	(3.90)	(6.24)
Decrease/(Increase) in other current assets	(0.29)	(1.91)
Increase/(decrease) in trade payables	9.18	6.71
Increase/(decrease) in provisions and other liabilities	(4.14)	(13.36)
Increase/(decrease) in other financial liabilities	4.63	(2.53)
Cash generated from operations	137.94	141.41
Income tax paid	(22.00)	(4.50)
Net cash generated from operating activities (A)	115.94	136.91
B. Cash flows from investing activities		
Acquisition of property, plant and equipment	(39.88)	(17.78)
Proceeds from sale of property, plant and equipment	2.75	-
Interest received	4.96	0.88
Net cash used in investing activities (B)	(32.17)	(16.91)
C. Cash flows from financing activities		
Interest paid	(26.52)	(28.55)
Net cash used in financing activities	(26.52)	(28.55)
Net increase/(decrease) in cash and cash equivalents (A + B + C)	57.25	91.45
Cash and cash equivalents at the beginning of the year	191.49	77.96
Cash and cash equivalents at end of the year	248.74	169.42
Note:		
(a) The above Statement of Cash Flows has been prepared under the "Indirect Method" as set out in the Indian Accounting Standard (Ind AS-7) - Statement of Cash Flows.		
(b) Cash and cash equivalents mentioned above comprise the following:		
	As at September 30, 2024	As at September 30, 2023
Cash on hand	1.31	1.27
Balances with banks		
- in current accounts	80.92	168.15
- in deposit accounts	166.51	-
Total cash and cash equivalents	248.74	169.42
(c) Net Debt Reconciliation		
	As at September 30, 2024	As at September 30, 2023
Particulars		
Opening balance of borrowings	500.00	575.00
Add:- Proceeds from borrowings during the year	-	-
Less:- Repayment of borrowings during the year	-	-
Closing balance of borrowings	500.00	575.00
For MEDINOVA DIAGNOSTIC SERVICES LIMITED		
	SURA SURENDRANATH REDDY	Digitally signed by SURA SURENDRANATH REDDY Date: 2024.10.29 13:05:43 +05'30'
Place: Hyderabad	DR. S. SURENDRANATH REDDY	
Date : 29-10-2024	CHAIRMAN	
	DIN 00108599	

M.ANANDAM & CO.,
CHARTERED ACCOUNTANTS

**Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results
of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015**

**Review Report to the Board of Directors
Medinova Diagnostic Services Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Medinova Diagnostic Services Limited (the "Company") for the quarter ended 30th September, 2024 and year to date results for the period 1st April, 2024 to 30th September, 2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M. Anandam & Co.,
Chartered Accountants
(Firm Regn.No.000125S)

Madhuri Digitally signed by
Chimalgi Madhuri Chimalgi
Date: 2024.10.29
13:29:03 +05'30'

Madhuri Chimalgi
Partner
Membership Number: 235955
UDIN: 24235955BKCIJZO4207

Place: Secunderabad
Date: 29-10-2024

MEDINOVA DIAGNOSTIC SERVICES LIMITED
CIN: L85110TG1993PLC015481

Regd. Office : H.No. 7-1-58, Unit No. 1/Flat No.301, 3rd Floor, Amrutha Business Complex, Ameerpet, Hyderabad - 500 016.

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30th September, 2024

(Rs. in Lakhs)

Sl. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2024 (Unaudited)	30.06.2024 (Unaudited)	30.09.2023 (Unaudited)	30.09.2024 (Unaudited)	30.09.2023 (Unaudited)	31.03.2024 (Audited)
1	Income:						
	(a) Revenue from Operations	197.70	185.51	221.81	383.21	404.20	778.12
	(b) Other Income	2.16	1.99	2.82	4.15	5.92	25.78
	Total Income	199.86	187.50	224.63	387.36	410.12	803.90
2	Expenses						
	(a) Cost of Materials Consumed	13.74	16.54	24.53	30.28	46.26	85.51
	(b) Employee Benefits Expense	41.96	41.66	42.85	83.62	91.18	173.34
	(c) Testing Fees	19.84	15.02	19.17	34.86	31.02	60.06
	(d) Finance Costs	12.60	12.47	14.49	25.07	28.83	57.40
	(e) Depreciation and amortisation expenses	3.59	3.15	3.16	6.74	6.00	12.30
	(f) Other Expenses	73.79	76.81	82.66	150.60	160.65	313.62
	Total Expenses	165.52	165.65	186.86	331.17	363.94	702.23
3	Profit before Tax [1-2]	34.34	21.85	37.77	56.19	46.18	101.67
4	Tax Expense						
	(a) Current Tax	8.91	2.10	7.00	11.01	7.50	20.39
	(b) Earlier Year's Tax	-	-	0.01	-	0.01	0.01
	(c) Deferred Tax	0.66	3.12	1.00	3.78	4.52	6.00
	Total tax expense	9.57	5.22	8.01	14.79	12.04	26.40
5	Profit/Loss for the period (3-4)	24.77	16.63	29.76	41.40	34.14	75.27
6	Other Comprehensive Income						
	Items that will not be reclassified to Profit or Loss :						
	i) Remeasurement of defined benefit plans	-	-	-	-	-	1.63
	ii) Income tax relating to above	-	-	-	-	0.00	(0.41)
7	Total Comprehensive Income for the period (5+6)	24.77	16.63	29.76	41.40	34.14	76.49
8	Paid-up Equity Share capital (Face Value Rs 10/- per share)	995.68	995.68	995.68	995.68	995.68	995.68
9	Earnings per Equity Share (not annualised)						
	a) Basic (Rs.)	0.25	0.17	0.30	0.41	0.34	0.75
	b) Diluted (Rs.)	0.25	0.17	0.30	0.41	0.34	0.75

Notes

1. The above Standalone financial results of Medinova Diagnostic Services Limited ("the Company") have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2. The above standalone financial results were reviewed by the audit committee and approved by the Board of Directors in their respective meetings held on 29th October 2024. The statutory auditors have carried out limited review of the above results for the quarter and half year ended 30th September 2024. An unmodified report has been issued by them thereon.

3. The Company has one reportable segment (viz. Diagnostic Services) as per the requirements of Ind AS 108 "Operating Segments".

4. The Board of Directors of the Company in their meeting held on June 26th 2024 have considered and approved the proposed Scheme of Amalgamation of the Company ("Transferor Company") into and with the Parent Company, "Vijaya Diagnostic Centre Limited" (Transferee Company) with effect from April 01st 2024 ('the Appointed Date') under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013, and other rules and regulations framed thereunder ("Scheme").

The aforesaid Scheme is subject to the approval of Stock Exchanges, SEBI, Shareholders and Creditors of the respective companies and National Company Law Tribunal, and such other approvals, permissions, and sanctions of regulatory and other authorities as may be necessary.

For MEDINOVA DIAGNOSTIC SERVICES LIMITED

SURA
SURENDRANATH
REDDY

Digitally signed by SURA
SURENDRANATH REDDY
Date: 2024.10.29 12:59:37
+05'30'

Dr. S. SURENDRANATH REDDY

CHAIRMAN
DIN 00108599

Place: Hyderabad
Date: 29-10-2024

MEDINOVA DIAGNOSTIC SERVICES LIMITED
CIN: L85110TG1993PLC015481

Regd. Office : H.No. 7-1-58, Unit No. 1/Flat No.301, 3rd Floor, Amrutha Business Complex, Ameerpet, Hyderabad - 500 016.
Standalone Balance Sheet as at September 30, 2024

(Rs. in Lakhs)

Sl No.	Particulars	As at 30.09.2024 (Unaudited)	As at 31.03.2024 (Audited)
	ASSETS		
I	Non-current assets		
	(a) Property, plant and equipment	125.04	97.97
	(b) Intangible assets	3.73	3.64
	(c) Financial assets		
	(i) Investments	296.82	296.82
	(ii) Other financial assets	27.27	25.27
	(d) Deferred tax assets (net)	46.35	50.13
	(e) Non-current tax assets (net)	11.89	11.89
	Total non-current assets	511.10	485.72
II	Current assets		
	(a) Inventories	10.50	10.22
	(b) Financial assets		
	(i) Trade receivables	46.98	37.23
	(ii) Cash and cash equivalents	70.42	61.20
	(iii) Other financial assets	1.09	0.76
	(c) Other current assets	6.13	6.03
	Total current assets	135.12	115.44
	TOTAL ASSETS (I + II)	646.21	601.16
	EQUITY AND LIABILITIES		
I	Equity		
	(a) Equity share capital	995.68	995.68
	(b) Other Equity	(1,160.87)	(1,202.28)
	Total equity	(165.19)	(206.60)
II	Liabilities		
	Non-current liabilities		
	(a) Financial liabilities		
	(i) Borrowings	500.00	500.00
	(b) Provisions	16.84	22.19
	Total non-current liabilities	516.84	522.19
III	Current liabilities		
	(a) Financial liabilities		
	(i) Trade payables		
	(a) Total outstanding dues of micro and small enterprises	0.80	3.03
	(b) Total outstanding dues of creditors other than micro and small enterprises	241.75	228.79
	(ii) Other financial liabilities	30.45	32.77
	(b) Other current liabilities	5.30	5.92
	(c) Provisions	13.16	13.16
	(d) Current tax liabilities (net)	3.09	1.90
	Total current liabilities	294.56	285.57
	Total liabilities (II + III)	811.40	807.76
	TOTAL EQUITY AND LIABILITIES (I + II + III)	646.21	601.16

For MEDINOVA DIAGNOSTIC SERVICES LIMITED

SURA
SURENDRANATH
REDDY

Digitally signed by SURA
SURENDRANATH REDDY
Date: 2024.10.29
13:01:14 +05'30'

Place: Hyderabad
Date: 29-10-2024

Dr. S. SURENDRANATH REDDY
CHAIRMAN
DIN 00108599

MEDINOVA DIAGNOSTIC SERVICES LIMITED

CIN: L85110TG1993PLC015481

Regd. Office : H.No. 7-1-58, Unit No. 1/Flat No.301, 3rd Floor, Amrutha Business Complex, Ameerpet, Hyderabad - 500 016.

Standalone Statement of Cash Flows

Particulars	(Rs. in Lakhs)	
	Half Year Ended September 30, 2024 (Unaudited)	Half Year Ended September 30, 2023 (Unaudited)
A Cash flow from operating activities		
Profit before tax	56.19	46.18
<i>Adjustments for:</i>		
Depreciation and amortisation expenses	6.74	6.00
Net (gain)/loss on sale of property, plant and equipment	3.20	-
Interest income	(0.29)	(0.81)
Provision for credit impaired receivables	-	6.00
Finance costs	25.07	28.83
Liabilities no longer required written back	-	0.19
Operating profit before changes in assets and liabilities	90.92	86.39
Changes in working capital:		
Decrease/(Increase) in trade receivables	(9.75)	10.00
Decrease/(Increase) in inventories	(0.28)	0.01
Decrease/(Increase) in other financial assets	(2.00)	(0.22)
Decrease/(Increase) in other tax assets	(2.01)	(4.82)
Decrease/(Increase) in other current assets	(0.10)	(1.63)
Increase/(Decrease) in trade payables	10.73	9.44
Increase/(Decrease) in provisions and other liabilities	(4.77)	(13.50)
Increase/(Decrease) in other financial liabilities	(0.87)	(2.61)
Cash generated from operations	81.87	83.07
Income tax paid	(9.00)	(4.50)
Net cash from operating activities	72.87	78.57
B Cash flows from investing activities		
Acquisition of property, plant and equipment	(39.88)	(17.78)
Proceeds from sale of property, plant and equipment	2.75	-
Interest received	-	0.70
Net cash used in investing activities	(37.13)	(17.08)
C Cash flows from financing activities		
Interest paid	(26.52)	(28.55)
Net cash from/(used in) financing activities	(26.52)	(28.55)
Net increase/ (decrease) in cash and cash equivalents (A + B + C)	9.22	32.94
Cash and cash equivalents at the beginning of the year	61.20	61.31
Cash and cash equivalents at end of the year	70.42	94.25
Note:		
(a) The above Statement of Cash Flow has been prepared under the "Indirect Method" as set out in the Indian Accounting Standard (Ind AS-7) - Statement of Cash Flows.		
(b) Cash and cash equivalents mentioned above comprise the following:		
	As at	As at
	September 30, 2024	September 30, 2023
Cash on hand	1.16	1.04
Balances with banks		
- in current accounts	69.26	93.21
Total cash and cash equivalents	70.42	94.25
(c) Net Debt Reconciliation		
	As at September 30,	
Particulars	2024	As at September 30, 2023
Opening balance of borrowings	500.00	575.00
Add:- Proceeds from borrowings during the year	-	-
Less:- Repayment of borrowings during the year	-	-
Closing balance of borrowings	500.00	575.00
For MEDINOVA DIAGNOSTIC SERVICES LIMITED		
Place: Hyderabad Date: 29-10-2024	Digitally signed by SURA SURA SURENDRANATH SURENDRANATH REDDY REDDY Date: 2024.10.29 13:01:57 +05'30' Dr. S. SURENDRANATH REDDY CHAIRMAN DIN 00108599	